open access

Ahead of print
Research paper
Published online: 2021-02-12
Get Citation

Study of serum progranulin level and its relation to microvascular complications in subjects with type 1 diabetes mellitus

Kamel Rohoma, Mabaheg Souka, Eman Elsayed, Shaimaa Mohamed, Reem Mahmoud Fathalla
DOI: 10.5603/DK.a2021.0009

open access

Ahead of print
Original articles (submitted)
Published online: 2021-02-12

Abstract

Background. Progranulin is expressed in various cells including adipocytes. Having an important role in inflammation, it could participate to development of diabetes and its complications. We aimed at assessing serum progranulin level in subjects with type 1 diabetes mellitus (T1DM) and its relation to microvascular complications.
Methods. 80 subjects were included: 40 subjects with T1DM with a disease duration of more than 5 years, 20 subjects with newly diagnosed T1DM, and 20 healthy subjects as a control. Microvascular complications were assessed by clinical examination and investigations.
Results. The mean serum progranulin level was significantly higher in T1DM subjects with disease duration more than 5 years (77.2 ± 159.8) and those with disease duration less than one year (12.8 ± 16.0) comparing to  healthy controls (p = 0.009, p = 0.032, respectively). However, no significant difference was found in the mean serum progranulin between the two diabetic groups (p 0.883). Serum progranulin level was significantly higher in patients with retinopathy  (p ≤ 0.001), nephropathy (p = 0.002) and neuropathy  (p = 0.007). However, in multivariate regression analysis serum progranulin was not independently associated with microvascular complications of diabetes.
Conclusion. Serum progranulin is higher in T1DM than control and was not independently associated with diabetic microvascular complications. 

Abstract

Background. Progranulin is expressed in various cells including adipocytes. Having an important role in inflammation, it could participate to development of diabetes and its complications. We aimed at assessing serum progranulin level in subjects with type 1 diabetes mellitus (T1DM) and its relation to microvascular complications.
Methods. 80 subjects were included: 40 subjects with T1DM with a disease duration of more than 5 years, 20 subjects with newly diagnosed T1DM, and 20 healthy subjects as a control. Microvascular complications were assessed by clinical examination and investigations.
Results. The mean serum progranulin level was significantly higher in T1DM subjects with disease duration more than 5 years (77.2 ± 159.8) and those with disease duration less than one year (12.8 ± 16.0) comparing to  healthy controls (p = 0.009, p = 0.032, respectively). However, no significant difference was found in the mean serum progranulin between the two diabetic groups (p 0.883). Serum progranulin level was significantly higher in patients with retinopathy  (p ≤ 0.001), nephropathy (p = 0.002) and neuropathy  (p = 0.007). However, in multivariate regression analysis serum progranulin was not independently associated with microvascular complications of diabetes.
Conclusion. Serum progranulin is higher in T1DM than control and was not independently associated with diabetic microvascular complications. 

Get Citation

Keywords

diabetes mellitus; microvascular complications; progranulin; T1DM

About this article
Title

Study of serum progranulin level and its relation to microvascular complications in subjects with type 1 diabetes mellitus

Journal

Clinical Diabetology

Issue

Ahead of print

Article type

Research paper

Published online

2021-02-12

DOI

10.5603/DK.a2021.0009

Keywords

diabetes mellitus
microvascular complications
progranulin
T1DM

Authors

Kamel Rohoma
Mabaheg Souka
Eman Elsayed
Shaimaa Mohamed
Reem Mahmoud Fathalla

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl